Mersana Therapeutics, Inc.
MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$29.08
Price0.00%
$0.00
1Y
Price
Market Cap
$145.364m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-64.2%
EBITDA Margin-68.5%
Net Profit Margin-29.0%
Free Cash Flow Margin-64.2%
EBITDA Margin-68.5%
Net Profit Margin-29.0%
Free Cash Flow MarginRevenue
$33.180m
-18.1%
1y CAGR+10.2%
3y CAGR+15436.7%
5y CAGREarnings
-$70.081m
-1.3%
1y CAGR+24.8%
3y CAGR+13.6%
5y CAGREPS
-$14.09
+0.2%
1y CAGR+31.4%
3y CAGR+25.9%
5y CAGRBook Value
-$59.537m
$62.686m
Assets$122.223m
Liabilities$2.293m
DebtDebt to Assets
3.7%
-
Debt to EBITDAFree Cash Flow
-$74.371m
+9.8%
1y CAGR-56.7%
3y CAGR-26.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company